

17 November 2023

Hellenic Dynamics plc
("Hellenic Dynamics" or the "Company")

Timetable for the Proposed Capital Reorganisation

London, 16 November 2023, Hellenic Dynamics Plc (LSE: HELD), a medical cannabis cultivator with a dedicated focus on producing tetrahydrocannabinol ("THC") dominant strains of medical cannabis flowers for the burgeoning European medical cannabis markets, announces, further to the Mezzanine Loan and Posting of Circular announcement on 26 October 2023, the proposed timetable for the Capital Reorganisation.

EXPECTED TIMETABLE OF EVENTS

Publication and posting to Shareholders of the Circular	25 October 2023
General Meeting	9:00a.m. on 20 November 2023
Record date for the consolidation, subdivision and reclassification of the Existing Ordinary Shares	6:00 p.m. on 24 November 2023
Admission of the New Ordinary Shares	8:00 a.m. on 27 November 2023
CREST accounts credited with the New Ordinary Share	Shortly after 8:00 a.m. on 27 November 2023
Despatch of definitive share certificates in respect of the New Ordinary Shares	By 8 December 2023

Capitalised terms and definitions are as included in the circular published on 25 October 2023.

As a result of the Capital Reorganisation, the ISIN and SEDOL will changes on Admission of the New Ordinary Shares, as follows:

	Existing	New
ISIN	GB00B3CQW227	GB00BRXCFB77
Sedol	B3CQW22	BRXCFB7

As noted in the announcement on 26 October 2023, a copy of the circular, together with supporting documents, is available from the Company's website, www.hellenicdynamics.com.

The General Meeting will be held at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR on 20 November 2023 at 09:00 a.m. GMT.

Enquires:

Hellenic Dynamics plc
Davinder Rai

+44 (0)20 3818 7850
davinder@hellenicdynamics.com

Cairn Financial Advisers LLP
Emily Staples / Jo Turner

+44 (0)20 7213 0880

Peterhouse Capital
Lucy Williams / Charles Goodfellow

+44 (0)20 7469 0930

About Hellenic Dynamics plc

Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation and supply of THC ("tetrahydrocannabinol") - dominant strains of medical cannabis flowers, destined for the growing medical cannabis markets across Europe. Hellenic Dynamics' core strategy is to develop and operate its 40,000 square metre active cultivation licence from its 195,506 square metre facility located near Thessaloniki in Northern Greece. In full production, Hellenic Dynamics is capable of producing over 54,000 kg of dried flowers per annum.

Hellenic Dynamics will take advantage of its relatively low cost base resulting from a comparatively low cost of power, having its own running water supply and the labour rates for skilled and semi-skilled labour in Northern Greece.

25 European countries now allow medical cannabis via prescription and the European cannabis market is expected to reach €43.3 billion per annum by 2027. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and extracts are initially intended for export into Europe's largest market - Germany, in addition to other European markets including domestically in Greece.

As the first medical cannabis cultivator to obtain a listing on the main market for listed securities of the London Stock Exchange, Hellenic is significantly different to the number of CBD (Cannabidiol) related companies that have appeared over the recent years. Hellenic Dynamics cultivates THC-dominant medical cannabis flowers. THC-dominant medical cannabis products are only available via a medical prescription. Medicinal cannabis has been approved for use both in the United Kingdom and Germany, plus 23 other European countries, for conditions including but not limited to chronic pain, intractable chemotherapy-related nausea, anxiety, insomnia, Tourette's syndrome, substance use disorder, multiple sclerosis, IBS, spinal cord treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and glaucoma.

For further information please visit our website www.hellenicdynamics.com

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDBBDBGSBDGXL